登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Spike RBD >SPD-C82En

Biotinylated SARS-CoV-2 Spike RBD Protein (Y449H, E484K, N501Y), His,Avitag™ (MALS verified)

分子别名(Synonym)

Spike,S protein RBD,Spike glycoprotein Receptor-binding domain,S glycoprotein RBD,Spike protein RBD

表达区间及表达系统(Source)

Biotinylated SARS-CoV-2 Spike RBD Protein (Y449H, E484K, N501Y), His,Avitag (SPD-C82En) is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Lys 537 (Accession # QHD43416.1 (Y449H, E484K, N501Y)). The mutations Y449H, E484K, N501Y were identified in the SARS-CoV-2 variant C.1.2.

Predicted N-terminus: Arg 319

Request for sequence

蛋白结构(Molecular Characterization)

Spike RBD Structure

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™)

The protein has a calculated MW of 28.2 kDa. The protein migrates as 32-38 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Spike RBD SDS-PAGE

Biotinylated SARS-CoV-2 Spike RBD Protein (Y449H, E484K, N501Y), His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

Spike RBD SEC-MALS

The purity of Biotinylated SARS-CoV-2 Spike RBD Protein (Y449H, E484K, N501Y), His,Avitag (Cat. No. SPD-C82En) is more than 85% and the molecular weight of this protein is around 28-42 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

Spike RBD ELISA

Immobilized Biotinylated SARS-CoV-2 Spike RBD Protein (Y449H, E484K, N501Y), His,Avitag (Cat. No. SPD-C82En) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

Spike RBD ELISA

Immobilized Biotinylated SARS-CoV-2 Spike RBD Protein (Y449H, E484K, N501Y), His,Avitag (Cat. No. SPD-C82En) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) with a linear range of 0.2-6 ng/mL (Routinely tested).

Protocol

Spike RBD ELISA

Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 5 μg/mL (100 μL/well) can bind Biotinylated SARS-CoV-2 Spike RBD Protein (Y449H, E484K, N501Y), His,Avitag (Cat. No. SPD-C82En) with a linear range of 2-39 ng/mL (Routinely tested).

Protocol

Spike RBD ELISA

Immobilized Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) at 1 μg/mL (100 μL/well) can bind Biotinylated SARS-CoV-2 Spike RBD Protein (Y449H, E484K, N501Y), His,Avitag (Cat. No. SPD-C82En) with a linear range of 0.1-3 ng/mL (Routinely tested).

Protocol

 
评论(0)
  1. 774XXXXXXX
  2. 5人赞
  3. I have been using the unconjugated FMC63 for a while and as soon as we knew about the conjugated FMC63 we wanted to use this as it will be saving us 1.5 hours in the staining procedure. We used this antibody and we were able to see a better seperation of positive and negative poulations. Its easy to use and 1:25 dilution works really well. I will recommend this 200%
  4. >
  5. 2022-2-26
  1. 156XXXXXXX8
  2. 0人赞
  3. 该抗体目前主要用于细胞转染后阳性细胞转染效率检测,实验过程中抗体的高灵敏度及识别特异性,能够真实有效的反映出结果的准确性,且重复性,后期实验需要将会继续订购。
  4. >
  5. 2022-12-13
  1. 156XXXXXXX8
  2. 0人赞
  3. 该产品性能稳定,不同批次实验数据重复性较一直,能充分反映实验结果可信和真实性,同时能够充分满足实验早期的预实验的需求,肯定会继续回购。
  4. >
  5. 2023-3-31
 
ACRO质量管理体系
 
 

背景(Background)

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

 

前沿进展

Clade 2.3.4.4b but not historical clade 1 HA replicating RNA vaccine protects against bovine H5N1 challenge in mice
Hawman, Tipih, Hodge et al
Nat Commun (2025) 16 (1), 655
Abstract: The ongoing circulation of influenza A H5N1 in the United States has raised concerns of a pandemic caused by highly pathogenic avian influenza. Although the United States has stockpiled and is prepared to produce millions of vaccine doses to address an H5N1 pandemic, currently circulating H5N1 viruses contain multiple mutations within the immunodominant head domain of hemagglutinin (HA) compared to the antigens used in stockpiled vaccines. It is unclear if these stockpiled vaccines will need to be updated to match the contemporary H5N1 strains. Here we show that a replicating RNA vaccine expressing the HA of an H5N1 isolated from a US dairy cow confers complete protection against homologous lethal challenge in mice. A repRNA encoding the HA of a clade 1 H5 from 2004 (A/Vietnam/1203/2004) as utilized by some stockpiled vaccines, confers only partial protection. Our data highlight the utility of nucleic acid vaccines to be rapidly updated to match emergent viruses of concern while demonstrating that contemporary bovine H5N1 viruses can evade immunity elicited by historical HA antigens.© 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Enhancing NA immunogenicity through novel VLP designs
Guzman Ruiz, Zollner, Hoxie et al
Vaccine (2024) 42 (24), 126270
Abstract: Current influenza virus vaccines poorly display key neuraminidase (NA) epitopes and do not robustly induce NA-reactive antibodies; instead, they focus on the induction of hemagglutinin (HA)-reactive antibodies. Next-generation influenza vaccines should be optimized in order to activate NA-reactive B cells and to induce a broadly cross-reactive and protective antibody response. We aimed at enhancing the immunogenicity of the NA on vaccines by two strategies: (i) modifying the HA:NA ratio of the vaccine preparation and (ii) exposing epitopes on the lateral surface or beneath the head of the NA by extending the NA stalk. The H1N1 glycoproteins from the influenza virus A/California/04/2009 strain were displayed on human immunodeficiency virus 1 (HIV-1) gag-based virus-like particles (VLP). Using the baculovirus insect cell expression system, we biased the quantity of surface glycoproteins employing two different promoters, the very late baculovirus p10 promoter and the early and late gp64 promoter. This led to a 1:1 to 2:1 HA:NA ratio, which was approximately double or triple the amount of NA as present on the wild-type influenza A virus (HA:NA ratio 3:1 to 5:1). Furthermore, by insertion of 15 amino acids from the A-New York/61/2012 strain (NY12) which prolongates the NA stalk (NA long stalk; NA-LS), we intended to improve the accessibility of the NA. Six different types of VLPs were produced and purified using a platform downstream process based on Capto-Core 700™ followed by Capto-Heparin™ affinity chromatography combined with ultracentrifugation. These VLPs were then tested in a mouse model. Robust titers of antibodies that inhibit the neuraminidase activity were elicited even after vaccination with two low doses (0.3 μg) of the H1N1 VLPs without compromising the anti-HA responses. In conclusion, our results demonstrate the feasibility of the two developed strategies to retain HA immunogenicity and improve NA immunogenicity as a future influenza vaccine candidate.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination
Aydillo, Gonzalez-Reiche, Stadlbauer et al
NPJ Vaccines (2022) 7 (1), 160
Abstract: A phase 1 clinical trial to test the immunogenicity of a chimeric group 1 HA (cHA) universal influenza virus vaccine targeting the conserved stalk domain of the hemagglutinin of influenza viruses was carried out. Vaccination with adjuvanted-inactivated vaccines induced high anti-stalk antibody titers. We sought to identify gene expression signatures that correlate with such induction. Messenger-RNA sequencing in whole blood was performed on the peripheral blood of 53 vaccinees. We generated longitudinal data on the peripheral blood of 53 volunteers, at early (days 3 and 7) and late (28 days) time points after priming and boosting with cHAs. Differentially expressed gene analysis showed no differences between placebo and live-attenuated vaccine groups. However, an upregulation of genes involved in innate immune responses and type I interferon signaling was found at day 3 after vaccination with inactivated adjuvanted formulations. Cell type deconvolution analysis revealed a significant enrichment for monocyte markers and different subsets of dendritic cells as mediators for optimal B cell responses and significant increase of anti-stalk antibodies in sera. A significant upregulation of immunoglobulin-related genes was only observed after administration of adjuvanted vaccines (either as primer or booster) with specific induction of anti-stalk IGVH1-69. This approach informed of specific immune signatures that correlate with robust anti-stalk antibody responses, while also helping to understand the regulation of gene expression induced by cHA proteins under different vaccine regimens.© 2022. The Author(s).
Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates
Flynn, Weber, Cejas et al
Vaccine (2022) 40 (32), 4412-4423
Abstract: In response to immune pressure, influenza viruses evolve, producing drifted variants capable of escaping immune recognition. One strategy for inducing a broad-spectrum immune response capable of recognizing multiple antigenically diverse strains is to target conserved proteins or protein domains. To that end, we assessed the efficacy and immunogenicity of mRNA vaccines encoding either the conserved stem domain of a group 1 hemagglutinin (HA), a group 2 nucleoprotein (NP), or a combination of the two antigens in mice, as well as evaluated immunogenicity in naïve and influenza seropositive nonhuman primates (NHPs). HA stem-immunized animals developed a robust anti-stem antibody binding titer, and serum antibodies recognized antigenically distinct group 1 HA proteins. These antibodies showed little to no neutralizing activity in vitro but were active in an assay measuring induction of antibody-dependent cellular cytotoxicity. HA-directed cell-mediated immunity was weak following HA stem mRNA vaccination; however, robust CD4 and CD8 T cell responses were detected in both mice and NHPs after immunization with mRNA vaccines encoding NP. Both HA stem and NP mRNA vaccines partially protected mice from morbidity following lethal influenza virus challenge, and superior efficacy against two different H1N1 strains was observed when the antigens were combined. In vivo T cell depletion suggested that anti-NP cell-mediated immunity contributed to protection in the mouse model. Taken together, these data show that mRNA vaccines encoding conserved influenza antigens, like HA stem and NP in combination, induce broadly reactive humoral responses as well as cell-mediated immunity in mice and NHPs, providing protection against homologous and heterologous influenza infection in mice.Copyright © 2022 Elsevier Ltd. All rights reserved.
Showing 1-4 of 40 papers.
Powered by BizGenius
 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定